Sentence examples for vector safety from inspiring English sources

Effective gene therapy requires regulated gene expression and vector safety.

In considering the viral gene delivery vector safety concerns regarding the risk of excessive immune response (adenovirus) and insertion mutagenesis (retroviruses), the use of non-viral vectors can overcome the mentioned safety problems [12].

We now describe a new assay for assessing vector safety that recapitulates naturally occurring insertions into Lmo2 and other T-cell proto-oncogenes leading to a preleukemic developmental arrest in primary murine thymocytes cultured in vitro.

While currently available preclinical safety models have been used for evaluating vector safety, none have predicted or reproduced the recurrent LMO2 integrations seen in previous X-linked severe combined immunodeficiency (X-SCID) and Wiskott Aldrich clinical gene therapy trials.

For many gene therapy applications, finding ways to counter the immunostimulatory properties of plasmid DNA vectors is an important approach designed to enhance the vector safety profile, thereby increasing its effective therapeutic index.

These findings highlight the need for detailed mechanistic analysis of tumor readouts in preclinical animal models assessing vector safety, and suggest the existence of other ill-defined risk factors for oncogenesis, including replicative stress, in gene therapy protocols targeting the hematopoietic compartment.

We examine appropriate vectors, safety issues, and rates of bone formation.

The initial success of iPSC production was achieved with retroviral vectors, but these vectors pose safety concerns for clinical application because the random integration of the retroviral vectors into the genome increases genomic instability [ 93].

Dropulic spent ten months in 2001 testing the HIV vector's safety profile using human tissue in mice.

However, the use of plasmid DNA as a carrier of the vector raises safety concerns due to the undesirable administration of bacterial sequences.

The Food & Drug Administration gave him the green light in December to enroll a handful of patients for early-stage clinical trials at the University of Pennsylvania to further determine the vector's safety.